Table 2.
LVMI, LV Geometric Patterns, Hemodynamics, and Biochemical Profile for the Two Study Groups
Allopurinol Users N=96 |
Control Subjects N=96 |
P-Value | |
---|---|---|---|
LVM (g) | 161.50 (128.25, 207.00) | 140.50 (117.75, 189.50) | 0.022 |
LVMI (g/m2) | 81.50 (68.00, 106.75) | 79.00 (66.00, 97.75) | 0.340 |
LVMI (g/h2.7) | 44.58 (35.53, 54.16) | 41.20 (31.07, 49.66) | 0.046 |
RWT | 0.345 (0.270, 0.428) | 0.340 (0.263, 0.420) | 0.849 |
LV geometric patterns | 0.345 | ||
Normal geometry (NL) | 53 (55.2%) | 63 (65.6%) | |
Concentric remodeling (CR) | 21 (21.9%) | 17 (17.7%) | |
Eccentric hypertrophy (EH) | 16 (16.7%) | 9 (9.4%) | |
Concentric hypertrophy (CH) | 6 (6.2%) | 7 (7.3%) | |
Ejection fraction (%) | 0.859 | ||
Normal ≥50 | 50 (52.1%) | 54 (56.3%) | |
Mild dysfunction 40–49 | 17 (17.7%) | 18 (18.7%) | |
Moderate dysfunction 30–39 | 12 (12.5%) | 11 (11.5%) | |
Severe dysfunction ˂30 | 17 (17.7%) | 13 (13.5%) | |
SBP (mmHg) | 126.91 ± 19.26 | 129.23 ± 22.68 | 0.445 |
DBP (mmHg) | 71.06 ± 12.81 | 69.74 ± 11.95 | 0.460 |
HR (beat/min) | 70.00 (63.00, 83.00) | 71.00 (62.00, 82.00) | 0.895 |
Biochemistry | |||
HbA1C (%)a | 7.00 (6.13, 7.70) | 7.65 (6.48, 9.22) | 0.004 |
eGFR (mL/min/1.73 m2)b | 33.50 (20.75, 49.25) | 60.00 (38.25, 60.00) | 0.000 |
Serum creatinine (mg/dL)b | 1.89 (1.21, 2.81) | 1.13 (0.90, 1.63) | 0.000 |
Total cholesterol (mg/dL) | 131.50 (109.70, 172.20) | 131.30 (111.39, 158.31) | 0.864 |
LDL-cholesterol (mg/dL) | 77.30 (58.00, 102.50) | 77.34 (54.14, 98.42) | 0.651 |
HDL-cholesterol (mg/dL) | 35.58 (30.94, 42.92) | 36.74 (28.52, 44.37) | 0.871 |
Triglycerides (mg/dL) | 130.15 (90.49, 176.33) | 123.89 (89.82, 166.15) | 0.503 |
Notes: Data calculated based on the following number of patients; a(84 allopurinol: 82 control), b(94 allopurinol: 96 control).
Abbreviations: g, gram; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVM, left ventricular mass; LVMI; left ventricular mass index; RWT, relative wall thickness; LV, left ventricle.